TESTOSTERONE REPLACEMENT THERAPY IN MEN WITH TYPE 2 DIABETES AND FAILURE TESTOSTERONE SYNDROME

Authors

  • Luchitskiy V. Ye. SI «V. P. Komissarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine», Kyiv
  • Luchitskiy Ye. V. SI «V. P. Komissarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine», Kyiv
  • Tronko M. D. SI «V. P. Komissarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine», Kyiv

DOI:

https://doi.org/10.21856/j-PEP.2016.2.05

Keywords:

testosterone, type 2 diabetes mellitus, male, hormone replacement therapy

Abstract

It was studied the influence of testosterone replacement therapy with prolonged action on the
functional state of the pituitary-genital system, clinical symptoms of androgendeficiency in patients
with type 2 diabetes (DMt2) with androgendeficiency. The study involved 35 male patients with DMt2
aged 39–72 years, duration of diabetes 2–14 years and total testosterone (T) levels < 10.4 nmol/l.
For the purpose of replacement testosterone treatment was used (1000 mg) of the oil solution of
testosterone undecanoate. After 3 and 6 months after initiation of treatment there was a significant
increase in total testosterone concentration 14.6 ± 0.9 nmol/l and 17.0 ± 0.7 nmol/l, respectively vs
8.3 ± 0.5 nmol/l before treatment (p < 0.05). Changes in the average levels of estradiol and lutropin
during treatment were not observed. No clinically significant side effects were not detected. Taking
long-acting testosterone undecanoate injection led to normalization of the total testosterone levels
and improve erectile function in men with type 2 diabetes and androgendeficiency.

References

Dandona P, Dhindsa S. J Clin Endocrin Metab 2011; 96:2643-2651.

Kalyani RR, Dobs AS. Curr Opin Endocrinol Diab Obes 2007; 14:226-234.

Corona G, Mannucci T, Petrone L, et al. Int J Impot Res 2006; 18(2):190-197.

Selvin E, Feinleib M, Zhang L, et al. Diabetes Care 2007; 30:234-238.

Dhindsa S, Miller MG, McWhirter CL, et al. Diabetes Care 2010; 33:1186-1192.

Oh JY, Barrett-Connor E, Wedick NM. Diabetes Care 2002; 25:55-60.

Stellato RK, Feldman HA, Hamdy O, et al. Diabetes Care 2000; 23:490-494.

Svatberg J, Jenssen T. Sundsfiord J. Jorde R. Diabetes Metab 2004; 30:29-34.

Keating NL, O’Malley AJ, Smith MR. J Clin Oncol 2006; 24:448-456.

Mulligan T, Frick MF, Zuraw OC, et al. Int Clin Pract 2006; 60:762-769.

Kong AP, Chan NN, Chan JC. Curr Diabetes Rev 2006; 2(4):397-407.

Wu FC, von Eckardstein A. Endocr Rev 2003; 24:183-217.

Nieschlag E, Behre HM. Clinical uses of testosterone in hypogonadism and other conditions. In Testosterone, Action, Deficiency. Substitution, eds. Nieschlag E., Behre HM., Cambridge Univ, 2004: 375-404.

Buvat J. Newsbulletin ISSM 2009; 28:12-18.

Edelstein D, Bazaria Sh. Expert Opin Pharmacother 2010; 11(12):2095- 2106.

Jones TH, et al. Diabetes Care 2011; 34:828-837.

Hackett G, Cole N, Deshpande A, et al. Presented at the European Society of Sexual Medicine meeting, Milan, 2011.

Dhataria K, Nagi D, Jones TH. Pract Diab Int 2010; 27(9):408-412.

Edelstein D, Bazaria Sh. Expert Opin Pharmacother 2010; 11(12):2095-2106.

Edelstein D, Basaria AS. Int J Impot Res 2008; 20(4):378-387

Downloads

Published

2016-06-08

How to Cite

Luchitskiy, V. Y., Luchitskiy, Y. V., & Tronko, M. D. (2016). TESTOSTERONE REPLACEMENT THERAPY IN MEN WITH TYPE 2 DIABETES AND FAILURE TESTOSTERONE SYNDROME. Problems of Endocrine Pathology, 56(2), 35-41. https://doi.org/10.21856/j-PEP.2016.2.05

Issue

Section

CLINICAL ENDOCRINOLOGY

Most read articles by the same author(s)